|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
|
US6107494A
(en)
*
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
GB9423172D0
(en)
*
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
GB9704208D0
(en)
*
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
|
PT864582E
(pt)
*
|
1997-03-14 |
2003-10-31 |
Aventis Pharma Gmbh |
1,4-benzotiazepina-1,1-dioxidos hipolipidemicos
|
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
|
CZ20012341A3
(cs)
|
1998-12-23 |
2001-12-12 |
G. D. Searle Llc Corparate Patent Department |
Kombinace inhibitorů transferoního proteinu cholesterylesterů a derivátů kyseliny fibrové pro kardiovaskulární indikace
|
|
WO2000038722A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
|
|
EP1340508A1
(en)
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
|
WO2000038723A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
|
HUP0104745A3
(en)
|
1998-12-23 |
2003-01-28 |
G D Searle Llc Chicago |
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
|
|
WO2000038727A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
|
|
IL143946A0
(en)
|
1998-12-23 |
2002-04-21 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein for cardiovascular indications
|
|
CA2362147A1
(en)
*
|
1999-02-12 |
2000-08-17 |
Steve A. Kolodziej |
1,2-benzothiazepines for the treatment of hyperlipidemic diseases
|
|
DE19916108C1
(de)
|
1999-04-09 |
2001-01-11 |
Aventis Pharma Gmbh |
Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
|
|
GB9914745D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Knoll Ag |
Therapeutic agents
|
|
FR2796070B1
(fr)
*
|
1999-07-06 |
2003-02-21 |
Lipha |
Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
US6794544B2
(en)
|
2000-03-10 |
2004-09-21 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
|
US7879840B2
(en)
|
2005-08-25 |
2011-02-01 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
|
US7718644B2
(en)
|
2004-01-22 |
2010-05-18 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
|
|
US7393652B2
(en)
|
2000-05-10 |
2008-07-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
|
|
US8022058B2
(en)
|
2000-05-10 |
2011-09-20 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
|
US20020183307A1
(en)
*
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002053548A1
(en)
*
|
2000-12-27 |
2002-07-11 |
Banyu Pharmaceutical Co.,Ltd. |
Benzothiazepine derivatives
|
|
GB0121337D0
(en)
*
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
BRPI0212346B1
(pt)
|
2001-09-08 |
2016-02-02 |
Albireo Ab |
Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica.
|
|
WO2003040127A1
(en)
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
|
|
MXPA04006255A
(es)
|
2002-01-17 |
2004-09-27 |
Pharmacia Corp |
Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
|
|
KR20040088519A
(ko)
|
2002-02-22 |
2004-10-16 |
뉴 리버 파마슈티칼스, 인크. |
활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US7312208B2
(en)
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
|
US7544678B2
(en)
|
2002-11-05 |
2009-06-09 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
|
|
GB0304194D0
(en)
*
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2004220548A1
(en)
|
2003-03-07 |
2004-09-23 |
The Trustees Of Columbia University, In The City Of New York |
Type 1 ryanodine receptor-based methods
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
US8710045B2
(en)
|
2004-01-22 |
2014-04-29 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the ryanodine receptors
|
|
WO2005082874A1
(ja)
*
|
2004-02-27 |
2005-09-09 |
Asahi Kasei Pharma Corporation |
新規なベンゾチアゼピン及びベンゾチエピン化合物
|
|
US7704990B2
(en)
|
2005-08-25 |
2010-04-27 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
|
EP2367554A4
(en)
|
2008-11-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES
|
|
JO3131B1
(ar)
*
|
2010-04-27 |
2017-09-20 |
Glaxosmithkline Llc |
مركبات كيميائية
|
|
EP4137137A1
(en)
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
EP3777864A1
(en)
|
2010-11-08 |
2021-02-17 |
Albireo AB |
Ibat inhibitors for the treatment of liver diseases
|
|
AU2011326872C1
(en)
|
2010-11-08 |
2015-02-19 |
Albireo Ab |
A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
|
|
JP2015003861A
(ja)
*
|
2011-10-18 |
2015-01-08 |
株式会社カネカ |
（ｒ）−２−アミノ−２−エチルヘキサノールの製造法
|
|
EA201891154A1
(ru)
|
2011-10-28 |
2019-02-28 |
ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи |
Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
|
|
BR112014010228B1
(pt)
|
2011-10-28 |
2020-09-29 |
Lumena Pharmaceuticals Llc |
Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
|
|
EP2968230A2
(en)
|
2013-03-15 |
2016-01-20 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
JP2016514678A
(ja)
|
2013-03-15 |
2016-05-23 |
ルメナ ファーマシューティカルズ エルエルシー |
バレット食道と胃食道逆流性疾患を処置するための胆汁酸再利用阻害剤
|
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
|
US10709755B2
(en)
|
2014-06-25 |
2020-07-14 |
Elobix Ab |
Solid formulation and method for preventing or reducing coloration thereof
|
|
EP3177600B1
(en)
|
2014-08-05 |
2018-05-23 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Synthesis of benzothiazepines
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
ES2874669T3
(es)
|
2016-02-09 |
2021-11-05 |
Albireo Ab |
Formulación oral de colestiramina y uso de la misma
|
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
WO2017138878A1
(en)
|
2016-02-09 |
2017-08-17 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
WO2019032027A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
|
|
CA3071285A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
Cholestyramine granules, oral cholestyramine formulations and use thereof
|
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
JP7391048B2
(ja)
|
2018-06-05 |
2023-12-04 |
アルビレオ・アクチボラグ |
ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
IL279468B2
(en)
|
2018-06-20 |
2024-11-01 |
Albireo Ab |
Crystallographic modifications of odeviccibat
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
TWI835997B
(zh)
|
2019-02-06 |
2024-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻氮呯化合物及其用作膽酸調節劑之用途
|
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
CN113677398B
(zh)
|
2019-02-06 |
2024-07-23 |
阿尔比里奥公司 |
苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
|
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
|
MX2021009622A
(es)
|
2019-02-12 |
2021-11-04 |
Mirum Pharmaceuticals Inc |
Metodos para tratar la colestasis.
|
|
JP2023504647A
(ja)
|
2019-12-04 |
2023-02-06 |
アルビレオ・アクチボラグ |
ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
TW202134218A
(zh)
|
2019-12-04 |
2021-09-16 |
瑞典商艾爾比瑞歐公司 |
苯并噻氮呯化合物及其作為膽酸調節劑之用途
|
|
PT4069360T
(pt)
|
2019-12-04 |
2024-03-06 |
Albireo Ab |
Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
|
|
MX2022006731A
(es)
|
2019-12-04 |
2022-06-09 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
|
|
WO2021110884A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CN114761018A
(zh)
|
2019-12-04 |
2022-07-15 |
阿尔比里奥公司 |
苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
WO2021110885A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
TW202134220A
(zh)
|
2019-12-04 |
2021-09-16 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2022029101A1
(en)
|
2020-08-03 |
2022-02-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
EP4188541A1
(en)
|
2020-08-03 |
2023-06-07 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2022101379A1
(en)
|
2020-11-12 |
2022-05-19 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
AU2021379076A1
(en)
|
2020-11-12 |
2023-06-08 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
JP2024500309A
(ja)
|
2020-12-04 |
2024-01-09 |
アルビレオ エービー |
ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
|
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
AU2023285002A1
(en)
|
2022-06-09 |
2024-12-05 |
Albireo Ab |
Treating hepatitis
|
|
WO2024008766A1
(en)
|
2022-07-05 |
2024-01-11 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2024094841A1
(en)
|
2022-11-03 |
2024-05-10 |
Albireo Ab |
Treating alagille syndrome (algs)
|
|
US20240207286A1
(en)
|
2022-12-09 |
2024-06-27 |
Albireo Ab |
Asbt inhibitors in the treatment of renal diseases
|